The 20 references in paper M. Batyushin M., L. Rudenko I., A. Kogin A., V. Golub V., O. Dankin N., I. Grekova A., М. Батюшин М., Л. Руденко И., А. Кожин А., В. Голуб В., О. Данькин Н., И. Грекова А. (2014) “Атипичный гемолитико-уремический синдром. Клинические наблюдения // Atypical hemolytic uremic syndrome. Case reports” / spz:neicon:nefr:y:2014:i:5:p:80-84

1
Лора Ш, Фремю-Бачи В. Атипичный гемолитикоуремический синдром. Нефрология 2012; 16(2): 16-48
(check this in PDF content)
2
Constantinescu AR, Bitzan M, Weiss LS et al. Non-enteropathic hemolytic uremic syndrome: causes and short-term course. Am J Kidney Dis 2004; (43): 976-982
(check this in PDF content)
3
Bienaimé F., Dragon-Durey M-A, Regnier CH et al. Mutations in components of complement influences the outcome of Factor Iassociated atypical hemolytic uremic syndrome. Kidney Int 2009; (77): 339-349
(check this in PDF content)
4
Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009;(361): 1676–1687
(check this in PDF content)
5
Noris M, Caprioli J, Bresin E et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010; (5): 1844–1859
(check this in PDF content)
6
Sullivan M, Erlic Z, Hoffmann MM et al. Epidemiological approach to identifying genetic predispositions for atypical hemolytic uremic syndrome. Ann Hum Genet 2010; (74): 17-26
(check this in PDF content)
7
Trascasa M, Sánchez-Corral P, Rodríguez de Córdoba S. Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. Hum Mol Genet 2005; (14): 703-712
(check this in PDF content)
8
Westra D, Volokhina E, van der Heijden E et al. Genetic disorders in complement (regulating) genes in patients with atypical haemolytic uraemic syndrome (aHUS). Nephrol Dial Transplant 2010; (25): 2195–2202
(check this in PDF content)
9
Geerdink LM, Westra D, van Wijk JAE et al. Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics. Pediatr Nephrol 2012; (27): 1283–1291
(check this in PDF content)
10
Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA et al. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2007; (18): 2392–2400
(check this in PDF content)
11
Caprioli J, Noris M, Brioschi S et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006; (108): 1267–1279
(check this in PDF content)
12
Fremeaux-Bacchi V, Dragon-Durey MA, Blouin J et al. Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome. J Med Genet 2004;(41): 84
(check this in PDF content)
13
Kavanagh D, Kemp EJ, Mayland E et al. Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome. J Am Soc Nephrol 2005; (16): 2150–2055
(check this in PDF content)
14
Kavanagh D, Goodship THJ. Atypical Hemolytic Uremic Syndrome, Genetic Basis, and Clinical Manifestations. Hematology 2011; (15): 15-20
(check this in PDF content)
15
Попа АВ, Лифшиц ВИ, Эмирова ХМ и др. Современные представления об атипичном гемолитико-уремическом синдроме. Педиатрия 2011; 90 (4): 134-140
(check this in PDF content)
16
Loirat C, Frémeaux-Bacchi V. Atypical hemolytic uremic syndrome. Loirat and Frémeaux-Bacchi Orphanet J of Rare Dis 2011; (6): 60
(check this in PDF content)
17
Scully M, Hunt BJ, Benjamin S et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. British J of Haematology 2012; 158(3): 323–335
(check this in PDF content)
18
Campistol JM, Arias M, Ariceta G et a. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia 2013; 33(1): 27-45
(check this in PDF content)
19
Schmidtko J, Peine S, El-Housseini Y. Treatment of Atypical Hemolytic Uremic Syndrome and Thrombotic Microangiopathies: A Focus on Eculizumab. Am J Kidney Dis 2013;61(2):289-299
(check this in PDF content)
20
Макарова ТП, Давлетбаева ГР, Поладова ЛВ и др. Опыт применения экулизумаба у ребенка с атипичным гемолитикоуремическим синдромом. Нефрология 2014; 18(3): 84-88 Авторы заявляют об отсутствии конфликта интересов.
(check this in PDF content)